What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical evidence from the TADPOLE study shows that dabrafenib plus trametinib significantly improves progression-free survival compared to vincristine plus carboplatin in the LGG cohort, with a median progression-free survival of 46.0 months versus 30.8 months. Although the HGG cohort did not have direct comparisons, indirect comparisons suggest a similar benefit. The evidence is compelling but lacks Phase 3 data, which prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for dabrafenib plus trametinib fall within NICE’s acceptable range, with an ICER around £30,000 per QALY. The committee noted that despite uncertainties, the potential benefits and unmet need justify the cost, making it defensible.
Is there quality-of-life evidence payers weigh? — Quality of life
While specific HRQoL data for children with glioma is limited, the committee acknowledged that the oral administration of dabrafenib plus trametinib could lead to improved quality of life by reducing hospital visits and allowing for more normal activities. However, the utility values were derived from adult populations, which may not fully capture the impact on children.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Dabrafenib plus trametinib has a favorable safety profile, with manageable adverse events reported in the TADPOLE study. The committee noted that the adverse effects were mostly mild to moderate, which supports a strong tolerability rating.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparator for LGG, vincristine plus carboplatin, is appropriate and widely used in clinical practice. For HGG, the use of temozolomide and best supportive care as comparators is also justified, although the HGG cohort lacked direct comparisons.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is representative of the intended patient population, focusing on children aged 1 to 17 years with BRAF V600E mutation-positive glioma. However, there are some limitations in subgroup analyses, particularly for HGG.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Dabrafenib plus trametinib can be integrated into existing care pathways with minimal disruption, as it is an oral treatment that reduces the need for hospital visits. This aligns well with current clinical practices for glioma management.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of implementing dabrafenib plus trametinib are manageable, especially considering the potential for reduced hospital visits and associated costs. The committee noted that the overall budget impact is justifiable given the expected benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily derived from a well-conducted Phase 2 study (TADPOLE) with a robust design. However, the lack of Phase 3 trials introduces some uncertainty, preventing a higher rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties related to the indirect comparisons and the extrapolation of survival data, the committee found the context of high unmet need and potential benefits to justify the treatment’s recommendation.
